Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses

Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses

Certain RGD-binding integrins are required for cell adhesion, migration, and proliferation and are overexpressed in most tumors, making them attractive therapeutic targets. However, multiple integrin antagonist drug candidates have failed to show efficacy in cancer clinical trials. In this work, we...

Full description

Bibliographic Details
Main Authors: Dranoff, Glenn (Author), Kwan, Byron Hua (Contributor), Zhu, Eric Franklin (Contributor), Tzeng, Alice (Contributor), Sugito, Harun R. (Contributor), Eltahir, Ahmed A. (Contributor), Ma, Botong (Contributor), Delaney, Mary K. (Contributor), Murphy, Patrick A. (Contributor), Kauke, Monique Jacqueline (Contributor), Angelini, Alessandro (Contributor), Momin, Noor (Contributor), Mehta, Naveen (Contributor), Maragh, Alecia M. (Contributor), Hynes, Richard O. (Contributor), Cochran, Jennifer R. (Contributor), Wittrup, Karl Dane (Contributor)
Other Authors: Massachusetts Institute of Technology. Department of Biological Engineering (Contributor), Massachusetts Institute of Technology. Department of Biology (Contributor), Massachusetts Institute of Technology. Department of Chemical Engineering (Contributor), Massachusetts Institute of Technology. Department of Mathematics (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor)
Format: Article
Language:English
Published: Rockefeller University Press, 2018-04-06T15:16:04Z.
Subjects:
Article
Online Access:Get fulltext

Similar Items

Similar Items